Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Short Interest Update

Jasper Therapeutics, Inc. (NASDAQ:JSPRWGet Free Report) was the recipient of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 11,400 shares, a decline of 10.9% from the February 29th total of 12,800 shares. Based on an average daily trading volume, of 26,100 shares, the days-to-cover ratio is presently 0.4 days.

Hedge Funds Weigh In On Jasper Therapeutics

A hedge fund recently raised its stake in Jasper Therapeutics stock. Ionic Capital Management LLC boosted its holdings in Jasper Therapeutics, Inc. (NASDAQ:JSPRWFree Report) by 71.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 443,211 shares of the company’s stock after buying an additional 185,268 shares during the period. Ionic Capital Management LLC’s holdings in Jasper Therapeutics were worth $62,000 as of its most recent filing with the Securities and Exchange Commission.

Jasper Therapeutics Trading Up 9.3 %

Shares of JSPRW stock opened at $0.20 on Tuesday. The stock has a 50 day simple moving average of $0.18 and a 200 day simple moving average of $0.12. Jasper Therapeutics has a 1 year low of $0.04 and a 1 year high of $0.38.

About Jasper Therapeutics

(Get Free Report)

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation.

See Also

Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.